The Latest Pharma Jobs, News and Events

Revenue rose 2.8 percent to $8.18 billion, from $7.96 billion.

Commenting on the results, David Brennan, Chief Executive Officer, said:"Our second quarter performance reflects continued strong growth in our Emerging Markets and good performance for key brands Crestor, Seroquel and Symbicort. While revenue and Core EPS comparisons become more challenging in the second half of the year, we have increased our full year financial targets."

FDA advisory committee members have voted 7 to 1 to recommend the approval of Brilinta in patients with acute coronary syndrome, or blocked arteries. The FDA usually follows the advice of its advisory committee.